Cancers are quite common, but mostly very serious diseases and therefore belong to the most important areas of scientific research activity. Bladder cancer is one of the most common malignancies, it is a heterogeneous disease with significant diagnostic, therapeutic, and prognostic problems. It represents a disease with a variable course and a different response to therapy. The "conventional" prognostic markers used so far cannot reliably predict the natural course of the disease or estimate the tumor response to the chosen type of treatment. Molecular markers can provide us with the opportunity to diagnose a bladder tumor early, identify patients who are at risk of recurrence, or predict how tumors will respond to therapeutic approaches. As a result, diagnostics are found to help clinicians find the best therapeutic options for patients with bladder cancer. In this study, we focused on a brief description of potential molecular markers in bladder tumors in the context of precise diagnostics. Last but not least, we also focused on a new approach to the treatment of cancer using nanomaterials.

Institute of Medical Biology Genetics and Clinical Genetics Faculty of Medicine Comenius University Bratislava Slovak Republic

Zobrazit více v PubMed

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–249. doi: 10.3322/caac.21660. PubMed DOI

Ng K, Stenzl A, Sharma A, Vasdev N. Urinary biomarkers in bladder cancer: A review of the current landscape and future directions. Urol Oncol. 2021;39:41–51. doi: 10.1016/j.urolonc.2020.08.016. PubMed DOI

Repiska V, Radzo E, Biro C, Bevizova K, Bohmer D, Galbavy S. Endometrial cancer--prospective potential to make diagnostic process more specific. Neuro Endocrinol Lett. 2010;31:474–476. PubMed

Nieder AM, Soloway MS. Eliminate the term “superficial” bladder cancer. J Urol. 2006;175:417–418. doi: 10.1016/S0022-5347(05)00290-9. PubMed DOI

Bryan RT, Tselepis C. Cadherin switching and bladder cancer. J Urol. 2010;184:423–431. doi: 10.1016/j.juro.2010.04.016. PubMed DOI

Bratu O, Marcu D, Anghel R, Spinu D, Iorga L, Balescu I, Bacalbasa N, et al. Tumoral markers in bladder cancer (Review) Exp Ther Med. 2021;22:773. doi: 10.3892/etm.2021.10205. PubMed DOI PMC

Nagata M, Muto S, Horie S. Molecular Biomarkers in Bladder Cancer: Novel Potential Indicators of Prognosis and Treatment Outcomes. Dis Markers. 2016;2016:8205836. doi: 10.1155/2016/8205836. PubMed DOI PMC

Ascione CM, Napolitano F, Esposito D, Servetto A, Belli S, Santaniello A, Scagliarini S, et al. Role of FGFR3 in bladder cancer: Treatment landscape and future challenges. Cancer Treat Rev. 2023;115:102530. doi: 10.1016/j.ctrv.2023.102530. PubMed DOI

Keegan K, Johnson DE, Williams LT, Hayman MJ. Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3. Proc Natl Acad Sci U S A. 1991;88:1095–1099. doi: 10.1073/pnas.88.4.1095. PubMed DOI PMC

Harsanyi S, Novakova ZV, Bevizova K, Danisovic L, Ziaran S. Biomarkers of Bladder Cancer: Cell-Free DNA, Epigenetic Modifications and Non-Coding RNAs. Int J Mol Sci. 2022;23:13206. doi: 10.3390/ijms232113206. PubMed DOI PMC

Helsten T, Schwaederle M, Kurzrock R. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. Cancer Metastasis Rev. 2015;34:479–496. doi: 10.1007/s10555-015-9579-8. PubMed DOI PMC

AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov. 2017;7:818–831. doi: 10.1158/2159-8290.CD-17-0151. PubMed DOI PMC

Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4th ed. IARC Press; Lyon, France: 2016. PubMed DOI

Inamura K. Bladder Cancer: New Insights into Its Molecular Pathology. Cancers (Basel) 2018;10:100. doi: 10.3390/cancers10040100. PubMed DOI PMC

Zhang HH, Qi F, Shi YR, Miao JG, Zhou M, He W, Chen MF, et al. RNA interference-mediated vascular endothelial growth factor-C reduction suppresses malignant progression and enhances mitomycin C sensitivity of bladder cancer T24 cells. Cancer Biother Radiopharm. 2012;27:291–298. doi: 10.1089/cbr.2010.0919. PubMed DOI

Zhang C, Hu J, Li H, Ma H, Othmane B, Ren W, Yi Z, et al. Emerging biomarkers for predicting bladder cancer lymph node metastasis. Front Oncol. 2021;11:648968. doi: 10.46903/gjms/19.01.943. PubMed DOI PMC

Chen JX, Deng N, Chen X, Chen LW, Qiu SP, Li XF, Li JP. A novel molecular grading model: combination of Ki67 and VEGF in predicting tumor recurrence and progression in non-invasive urothelial bladder cancer. Asian Pac J Cancer Prev. 2012;13:2229–2234. doi: 10.7314/APJCP.2012.13.5.2229. PubMed DOI

Miettinen M, McCue PA, Sarlomo-Rikala M, Rys J, Czapiewski P, Wazny K, Langfort R, et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol. 2014;38:13–22. doi: 10.1097/PAS.0b013e3182a0218f. PubMed DOI PMC

Li Y, Ishiguro H, Kawahara T, Kashiwagi E, Izumi K, Miyamoto H. Loss of GATA3 in bladder cancer promotes cell migration and invasion. Cancer Biol Ther. 2014;15:428–435. doi: 10.4161/cbt.27631. PubMed DOI PMC

Asselin-Labat ML, Sutherland KD, Vaillant F, Gyorki DE, Wu D, Holroyd S, Breslin K, et al. Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor caspase-14. Mol Cell Biol. 2011;31:4609–4622. doi: 10.1128/MCB.05766-11. PubMed DOI PMC

Morris G, Stoychev S, Naicker P, Dirr HW, Fanucchi S. The forkhead domain hinge-loop plays a pivotal role in DNA binding and transcriptional activity of FOXP2. Biol Chem. 2018;399:881–893. doi: 10.1515/hsz-2018-0185. PubMed DOI

Inoue S, Mizushima T, Fujita K, Meliti A, Ide H, Yamaguchi S, Fushimi H, et al. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator. Hum Pathol. 2017;64:83–90. doi: 10.1016/j.humpath.2017.04.003. PubMed DOI

Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu I, Izumi K, Chang C, et al. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int. 2012;109:1716–1726. doi: 10.1111/j.1464-410X.2011.10706.x. PubMed DOI

DeGraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, et al. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS One. 2012;7:e36669. doi: 10.1371/journal.pone.0036669. PubMed DOI PMC

Sikic D, Eckstein M, Wirtz RM, Jarczyk J, Worst TS, Porubsky S, Keck B, et al. FOXA1 Gene expression for defining molecular subtypes of muscle-invasive bladder cancer after radical cystectomy. J Clin Med. 2020;9:994. doi: 10.3390/jcm9040994. PubMed DOI PMC

Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, Nichols PW, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994;331:1259–1264. doi: 10.1056/NEJM199411103311903. PubMed DOI

Amaral JD, Xavier JM, Steer CJ, Rodrigues CM. The role of p53 in apoptosis. Discov Med. 2010;9:145–152. PubMed

Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J, MacLean KH, et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell. 2003;4:321–328. doi: 10.1016/S1535-6108(03)00244-7. PubMed DOI

Shariat SF, Bolenz C, Karakiewicz PI, Fradet Y, Ashfaq R, Bastian PJ, Nielsen ME, et al. p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int. 2010;105:489–495. doi: 10.1111/j.1464-410X.2009.08742.x. PubMed DOI

Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004;22:1014–1024. doi: 10.1200/JCO.2004.03.118. PubMed DOI

Safe S, Imanirad P, Sreevalsan S, Nair V, Jutooru I. Transcription factor Sp1, also known as specificity protein 1 as a therapeutic target. Expert Opin Ther Targets. 2014;18:759–769. doi: 10.1517/14728222.2014.914173. PubMed DOI

Jiang NY, Woda BA, Banner BF, Whalen GF, Dresser KA, Lu D. Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2008;17:1648–1652. doi: 10.1158/1055-9965.EPI-07-2791. PubMed DOI

Jiang W, Jin Z, Zhou F, Cui J, Wang L, Wang L. High co-expression of Sp1 and HER-2 is correlated with poor prognosis of gastric cancer patients. Surg Oncol. 2015;24:220–225. doi: 10.1016/j.suronc.2015.05.004. PubMed DOI

Zhu J, Lu Z, Ke M, Cai X. Sp1 is overexpressed and associated with progression and poor prognosis in bladder urothelial carcinoma patients. Int Urol Nephrol. 2022;54:1505–1512. doi: 10.1007/s11255-022-03212-6. PubMed DOI

Hess J, Stelmach P, Eisenhardt A, Rübben H, Reis H, Schmid KW, Bachmann HS. Impact of BCL2 polymorphisms on survival in transitional cell carcinoma of the bladder. J Cancer Res Clin Oncol. 2017;143:1659–1670. doi: 10.1007/s00432-017-2404-8. PubMed DOI PMC

Itoi T, Yamana K, Bilim V, Takahashi K, Tomita F. Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients. Br J Cancer. 2004;90:200–205. doi: 10.1038/sj.bjc.6601454. PubMed DOI PMC

Pollack A, Wu CS, Czerniak B, Zagars GK, Benedict WF, McDonnell TJ. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res. 1997;3:1823–1829. doi: 10.1016/S0360-3016(97)00147-8. PubMed DOI

Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010;466:835–840. doi: 10.1038/nature09267. PubMed DOI PMC

Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92–105. doi: 10.1101/gr.082701.108. PubMed DOI PMC

Medina PP, Slack FJ. microRNAs and cancer: an overview. Cell Cycle. 2008;7:2485–2492. doi: 10.4161/cc.7.16.6453. PubMed DOI

Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature. 2010;467:86–90. doi: 10.1038/nature09284. PubMed DOI

Pasquinelli AE, Hunter S, Bracht J. MicroRNAs: a developing story. Curr Opin Genet Dev. 2005;15:200–205. doi: 10.1016/j.gde.2005.01.002. PubMed DOI

Wang SS, Fang YY, Huang JC, Liang YY, Guo YN, Pan LJ, Chen G. Clinical value of microRNA-198-5p downregulation in lung adenocarcinoma and its potential pathways. Oncol Lett. 2019;18:2939–2954. doi: 10.3892/ol.2019.10610. PubMed DOI PMC

Li X, Chen W, Li R, Chen X, Huang G, Lu C, Wen Z, et al. Bladder cancer diagnosis with a four-miRNA panel in serum. Future Oncol. 2022;18:3311–3322. doi: 10.2217/fon-2022-0448. PubMed DOI

Dyrskjøt L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, Fristrup N, et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 2009;69:4851–4860. doi: 10.1158/0008-5472.CAN-08-4043. PubMed DOI

Wang H, Li Q, Niu X, Wang G, Zheng S, Fu G, Wang Z. miR-143 inhibits bladder cancer cell proliferation and enhances their sensitivity to gemcitabine by repressing IGF-1R signaling. Oncol Lett. 2017;13:435–440. doi: 10.3892/ol.2016.5388. PubMed DOI PMC

Wiklund ED, Gao S, Hulf T, Sibbritt T, Nair S, Costea DE, Villadsen SB, et al. MicroRNA alterations and associated aberrant DNA methylation patterns across multiple sample types in oral squamous cell carcinoma. PLoS One. 2011;6:e27840. doi: 10.1371/journal.pone.0027840. PubMed DOI PMC

Chen YH, Wang SQ, Wu XL, Shen M, Chen ZG, Chen XG, Liu YX, et al. Characterization of microRNAs expression profiling in one group of Chinese urothelial cell carcinoma identified by Solexa sequencing. Urol Oncol. 2013;31:219–227. doi: 10.1016/j.urolonc.2010.11.007. PubMed DOI

Lenherr SM, Tsai S, Silva Neto B, Sullivan TB, Cimmino CB, Logvinenko T, Gee J, et al. MicroRNA expression profile identifies high grade, non-muscle-invasive bladder tumors at elevated risk to progress to an invasive phenotype. Genes (Basel) 2017;8:77. doi: 10.3390/genes8020077. PubMed DOI PMC

Chen CK, Liao J, Li MS, Khoo BL. Urine biopsy technologies: Cancer and beyond. Theranostics. 2020;10:7872–7888. doi: 10.7150/thno.44634. PubMed DOI PMC

Andersson E, Dahmcke CM, Steven K, Larsen LK, Guldberg P. Filtration device for on-site collection, storage and shipment of cells from urine and its application to DNA-based detection of bladder cancer. PLoS One. 2015;10:e0131889. doi: 10.1371/journal.pone.0131889. PubMed DOI PMC

Macgregor-Ramiasa M, McNicholas K, Ostrikov K, Li J, Michael M, Gleadle JM, Vasilev K. A platform for selective immuno-capture of cancer cells from urine. Biosens Bioelectron. 2017;96:373–380. doi: 10.1016/j.bios.2017.02.011. PubMed DOI

Lv Q, Gong L, Zhang T, Ye J, Chai L, Ni C, Mao Y. Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis. Clin Transl Oncol. 2016;18:322–330. doi: 10.1007/s12094-015-1372-1. PubMed DOI

Rahbari NN, Aigner M, Thorlund K, Mollberg N, Motschall E, Jensen K, Diener MK, et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology. 2010;138:1714–1726. doi: 10.1053/j.gastro.2010.01.008. PubMed DOI

Hong M, He G, Goh S, Low AWX, Tay KJ, Lim TKH, Yeong J, Khor LY, Lim TS. Biomarkers for Precision Urothelial Carcinoma Diagnosis: Current Approaches and the Application of Single-Cell Technologies. Cancers (Basel) 2021;13:260. doi: 10.3390/cancers13020260. PubMed DOI PMC

Wu J, Xu H, Ji H, Zhai B, Zhu J, Gao M, Zhu H, Wang X. Low Expression of Keratin17 is Related to Poor Prognosis in Bladder Cancer. Onco Targets Ther. 2021;14:577–587. doi: 10.2147/OTT.S287891. PubMed DOI PMC

Mariani AJ, Mariani MC, Macchioni C, Stams UK, Hariharan A, Moriera A. The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol. 1989;141:350–355. doi: 10.1016/S0022-5347(17)40763-4. PubMed DOI

Fajkovic H, Halpern JA, Cha EK, Bahadori A, Chromecki TF, Karakiewicz PI, Breinl E, Merseburger AS, Shariat SF. Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol. 2011;29:457–463. doi: 10.1007/s00345-011-0709-9. PubMed DOI

Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine. 2013;9:1–14. doi: 10.1016/j.nano.2012.05.013. PubMed DOI PMC

Muthu MS, Leong DT, Mei L, Feng SS. Nanotheranostics - application and further development of nanomedicine strategies for advanced theranostics. Theranostics. 2014;4:660–677. doi: 10.7150/thno.8698. PubMed DOI PMC

Manju S, Sreenivasan K. Gold nanoparticles generated and stabilized by water soluble curcumin-polymer conjugate: blood compatibility evaluation and targeted drug delivery onto cancer cells. J Colloid Interface Sci. 2012;368:144–151. doi: 10.1016/j.jcis.2011.11.024. PubMed DOI

Hou DY, Zhang NY, Wang MD, Xu SX, Wang ZJ, Hu XJ, Lv GT, et al. In situ constructed nano-drug depots through intracellular hydrolytic condensation for chemotherapy of bladder cancer. Angew Chem Int Ed Engl. 2022;61:e202116893. doi: 10.1002/anie.202116893. PubMed DOI

TMEM138: From Biological Functions to Diseases